To view this content, you need to sign in.
You should only be asked to sign in once. Not the case? Click here
Register now to access this content and more for free.
Venture firms exit PowderMed in Pfizer deal
Global pharmaceuticals group Pfizer paid a reported $400m to acquire PowderMed, a UK DNA-vaccines company backed by Advent Venture Partners, Abingworth Management, Oxford Bioscience Partners and SV Life Sciences.
